GILEAD SCIENCES INC
GILDNASDAQ🏆 #83 by market capEarnings Oct 28Biotech
$754.59▼ $40.97 (−5.43%)
Simulated price1h—
24h▼ 5.4%
7d—
14d—
30d—
1y—
🏦Market Cap
$164.99B
Mid Cap
📈Revenue Growth (YoY)
+5.5%
Slowing
📊Gross Margin
79.6%
High
💵FCF Margin
41.8%
Strong
⚖️P/S Ratio
5.4x
Fair
Otter Score
50
Weak
No chart data available for GILD.
Trading Snapshot
- Day Range
- $745.22 – $758.12
- 52-Week Range
- $108.46 – $157.29
- Volume
- $6.84B
- Avg Volume
- $8.85B
- Shares Outstanding
- 1.24B
- Next Earnings
- Sep 19, 2026
Fundamentals Snapshot
- Annual Revenue
- $30.41B
- Last Q Revenue
- $7.87B
- P/E Ratio
- —
- P/S Ratio
- 5.4x
- EPS (TTM)
- $-2.66
- Dividend Yield
- 3.67%
Why Investors Own GILD
- ✓High-growth profile — revenue up +4.8% YoY with expanding Biotech exposure.
- ✓Healthy economics — 27% gross margin and 18% free-cash-flow margin.
- ✓Deep pipeline with potential catalysts and durable IP.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$30.41B▲ +1.3% YoY
Gross Margin (TTM)
26.7%▲ +0.4% YoY
Operating Income (TTM)
$4.90B▲ +1.3% YoY
Free Cash Flow (TTM)
$5.60B▲ +1.3% YoY
About GILEAD SCIENCES INC
A company profile for GILEAD SCIENCES INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
50/100
Analyst Price Target
ⓘAverage Target
$914.45
▲ +21.2% Upside
High Target$1,044.24
Low Target$829.14
Based on 38 analysts
Latest News & Updates
🚀
Reuters·2h ago
GILEAD SCIENCES INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Bloomberg·5h ago
Analysts lift GILD price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Reuters·1d ago
GILEAD SCIENCES INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.